Study ID: COG AALL0932
Title:

Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)

Description:

The overall goal of Part I of this study is to collect information about the participant¿s leukemia and about the effects of the first phase of treatment, called Induction. Participants in this study have been diagnosed with Standard Risk B Lymphoblastic Leukemia (SR B-ALL), none, or only a few leukemia cells were found in your spinal fluid at diagnosis. B Lymphoblastic Leukemia (B-ALL) is a cancer of the blood cells that occurs in the bone marrow. The bone marrow is the soft tissue in the center of the bones where blood cells are made. B-ALL is a cancer in which young, abnormal, infection-fighting white blood cells, called ¿blasts¿, crowd out normal bone marrow cells and spread into the blood stream. Blasts can also spread to the brain, spinal cord, testicles, and other organs. The purpose of Part I of this study is to collect information on the leukemia and the effects of treatment. This will be given over 4 weeks. Participants will be offered the chance to take part in other parts of this study once the B-ALL risk group is known.

Location:
Fargo Region, Sioux Falls Region
Principal Investigator:
Kayelyn Wagner MD,Samuel Anim, MD
Disease:
ALL (Acute Lymphocytic Leukemia)
Stage:
Phase III

Status:

Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list